BTEE:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (USD)

ETF | Others |

Last Closing

USD 6.596

Change

+0.02 (+0.36)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-0.50 (-0.22%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.02 (+0.01%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.16 (-0.87%)

USD 588.35B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.08 (-0.54%)

USD 588.35B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+1.05 (+1.52%)

USD 266.08B
0QZO:LSE 0QZO

+2.10 (+1.92%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.26 (-0.85%)

USD 244.75B
0QZ3:LSE Qualcomm Inc.

+0.88 (+0.51%)

USD 202.26B
0R24:LSE Intel Corp.

-0.03 (-0.12%)

USD 196.14B

ETFs Containing BTEE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.57% 69% C- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.57% 69% C- 64% D
Trailing 12 Months  
Capital Gain 3.47% 29% F 41% F
Dividend Return 0.27% 35% F 40% F
Total Return 3.75% 24% F 38% F
Trailing 5 Years  
Capital Gain 17.53% 43% F 56% F
Dividend Return 1.76% 42% F 72% C
Total Return 19.29% 41% F 55% F
Average Annual (5 Year Horizon)  
Capital Gain 3.13% 36% F 45% F
Dividend Return 3.27% 35% F 44% F
Total Return 0.15% 39% F 41% F
Risk Return Profile  
Volatility (Standard Deviation) 17.06% 43% F 60% D-
Risk Adjusted Return 19.17% 34% F 48% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.